A Medicine Under Scrutiny
Concerns surrounding ColdRif cough syrup led to regulatory action in several Indian states in 2025 after reports connected the medicine with the deaths of children in Madhya Pradesh and Rajasthan.
State-Level Action
Authorities began examining reports of children becoming seriously ill after consuming the syrup. Subsequent testing raised concerns about possible contamination, prompting governments to take precautionary steps.
Concerns About Contamination
Punjab, Tamil Nadu, Madhya Pradesh and Delhi were among the states that took action at different points as officials reviewed the situation. Restrictions focused on the sale, distribution or use of the medicine.
Manufacturing Facility Investigated
One of the key concerns involved diethylene glycol (DEG), a toxic chemical reportedly detected in tested samples. Tamil Nadu authorities reported significant contamination in a sample associated with the manufacturer.
New Guidance for Young Children
Officials inspected the Sresan Pharmaceuticals facility in Tamil Nadu, where the product was made. Investigators reported serious irregularities, followed by regulatory action, including cancellation of the manufacturing licence and an order to stop operations.
Why Medicine Safety Matters
The Union Health Ministry also advised states and Union Territories that cough and cold medicines should not be prescribed to children younger than two years. The episode underlines the importance of manufacturing standards, testing, official advisories and professional medical guidance when medicines are used.